
Hypofractionated RT Noninferior After Mastectomy in Breast Cancer
Key Takeaways
- A 16-fraction PMRT+IMNI schedule achieved noninferior locoregional control versus 25 fractions, with very low absolute LRR rates and only 26 total LRR events.
- Secondary efficacy outcomes (DMFS, BCRFS, DFS, OS) were statistically indistinguishable between regimens, supporting clinical equivalence beyond locoregional endpoints.
In HypoMast-IMNI, 16-fraction radiotherapy was noninferior to 25 fractions for locoregional recurrence after mastectomy in high-risk breast cancer.
According to results from the phase 3 HypoMast-IMNI trial (NCT03856372), published in the Journal of Clinical Oncology, a 16-fraction
At a median follow-up of 58.1 months, the 5-year cumulative incidence of LRR was 1.7% (95% CI, 0.9%-2.9%) with HypoRT vs 2.2% (95% CI, 1.3%-3.5%) with ConvRT (HR, 0.69; 95% CI, 0.32-1.51; P = .017 for noninferiority). The trial recorded 26 LRR events: 11 in the HypoRT arm and 15 in the ConvRT arm. Noninferiority required the upper limit of the HR's 95% CI to fall below 1.61.
Phase 3 HypoMast-IMNI Study Design
Investigators at Fudan University Shanghai Cancer Center conducted the single-center, open-label trial.2 Between September 2018 and July 2022, they randomly assigned 1494 women 1:1 to HypoRT (42.56 Gy in 16 fractions) or ConvRT (50 Gy in 25 fractions). Both arms targeted the chest wall and regional lymph nodes, including the internal mammary nodes.1
Eligible patients were 18 to 70 years old. They had undergone mastectomy with negative margins and axillary lymph node dissection of at least 10 nodes. Their disease was pT1-4N2-3, pT3-4N1, or pT1-2N1 with at least 1 high-risk factor. Patients who had received neoadjuvant chemotherapy were excluded. LRR was the primary end point. Secondary end points were distant metastasis–free survival (DMFS), breast cancer recurrence–free survival (BCRFS), disease-free survival (DFS), overall survival (OS), and toxicity.
The data and safety monitoring committee saw event rates well below expectations and recommended the final analysis in 2025. The modified intention-to-treat population included 1429 patients (716 HypoRT; 713 ConvRT), and the data cutoff was October 2025. Nearly all patients (99.9%) received adjuvant chemotherapy, and about 91% were treated with simplified intensity-modulated radiotherapy.
Secondary End Points and Safety in HypoMast-IMNI
No secondary end point differed significantly between arms. Five-year DMFS was 92.3% with HypoRT vs 92.7% with ConvRT (HR, 1.00; 95% CI, 0.68-1.47; P = .987), and BCRFS was 91.8% vs 92.3% (HR, 0.99; 95% CI, 0.69-1.45; P = .980). Five-year DFS was 88.5% vs 89.4% (HR, 1.05; 95% CI, 0.76-1.44; P = .769), and OS was 95.1% vs 96.1% (HR, 1.21; 95% CI, 0.72-2.01; P = .476).1
Grade 3 acute skin toxicity was significantly lower with HypoRT (1.7% vs 12.2%; P < .001). Grade 1 to 2 skin pain (7.7% vs 23.3%; P < .001) and pruritus (26.7% vs 35.2%; P = .001) were also less frequent. So was late grade 1 to 2 hyperpigmentation (21.8% vs 27.2%; P = .019).1
Rates of grade 2 or higher radiation pneumonitis (2.0% vs 2.1%) and pulmonary fibrosis (1.3% in both arms) were low and comparable. No ischemic heart disease events were recorded, and there were no grade 4 toxicities or treatment-related deaths. Clinical lymphedema rates were similar (24.0% vs 23.0%; P = .575).
Clinical Context and Limitations
Together with other recent trials, the findings support hypofractionated regional nodal irradiation as an effective option, and the authors pointed to practical advantages of the shorter course: “increased institutional throughput and capacity, enhanced patient convenience, and reduced financial toxicity,” Xiaofang Wang, MD, PhD, and colleagues from the Department of Radiation Oncology at Fudan University Shanghai Cancer Center wrote in the paper.¹
In subgroup analyses, the effect of HypoRT on LRR was consistent with the primary analysis. Confidence intervals were wide in some subgroups because of low event numbers. The 5-year LRR rate was below 1% for patients with N1 disease and 4% or lower for those with N2-3 disease. Among patients with hormone receptor–negative/HER2-negative disease, the 5-year LRR rates were 6.4% with HypoRT and 8.2% with ConvRT.1
The authors noted that earlier randomized trials of postmastectomy hypofractionation either used older techniques or did not include IMNI. They attributed the low recurrence rates to contemporary systemic therapy, CT-based planning, and intensity-modulated techniques. A dedicated analysis of 133 patients with breast reconstruction showed no increased complication risk with HypoRT.
The authors listed several limitations. Excluding patients who received neoadjuvant chemotherapy limits applicability to current practice, including newer systemic therapies and strategies that omit PMRT after a pathologic complete response. All patients underwent axillary lymph node dissection, which limits direct application where sentinel node biopsy is used. Deep inspiration breath hold was used only in selected patients. The single-center design may limit generalizability, patients with N3b or N3c disease were not represented, and the low event rates reduced statistical power. The authors also said longer follow-up is needed to assess late toxicities, particularly cardiac effects.
The authors concluded that the 16-fraction regimen is noninferior to ConvRT for locoregional control, with a superior acute toxicity profile and excellent cardiopulmonary safety in this population.1
REFERENCES
1. Wang X, Zhang X, Chen X, et al. Hypofractionated versus conventionally fractionated postmastectomy radiotherapy with internal mammary node irradiation for high-risk breast cancer (HypoMast-IMNI): a randomized phase III trial. J Clin Oncol. Published online October 19, 2026. doi:10.1200/JCO-25-02843
2. Hypofractionated vs conventional fractionated postmastectomy radiotherapy for high risk breast cancer. ClinicalTrials.gov. Updated September 3, 2026. Accessed Nvoember 20, 2026. https://clinicaltrials.gov/study/NCT03856372
Related to this article








